Scientists from the University of Bochum have shown that the process of getting rid of fear can be significantly accelerated by activating certain neurons in the brain. This discovery could be an ...

Exl-111 is an investigational allergic Effector Cell Response Inhibitor (ECRI) targeting the IgE axis and is designed to disarm allergic effector cells at the source of activation ...

PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

A protein that is a key modulator of fat, glucose and cholesterol levels in the body usually works in tandem with another ...

Montelukast is a leukotriene receptor antagonist approved for the prophylactic and chronic treatment of asthma and the relief of allergic rhinitis.

Appetite is governed by gut hormones, not willpower. GLP-1 therapies extend natural satiety signals and expose the biology behind eating.

About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...